Skip to content

Population pharmacokinetic study of ciprofol in elderly patients under general anesthesia

Population pharmacokinetic study of ciprofol in elderly patients under general anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093796
Enrollment
Unknown
Registered
2024-12-12
Start date
2024-12-12
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Ciprofol Youth Group:Intravenous injection of ciprofol at 0.4 mg/kg during anesthesia induction, and continuous infusion of ciprofol at 0.8 mg/kg/h during anesthesia maintenance.
Ciprofol elderly Group:Intravenous injection of ciprofol at 0.4 mg/kg during anesthesia induction, and continuous infusion of ciprofol at 0.8 mg/kg/h during anesthesia maintenance.

Sponsors

General Hospital of the Southern Theater of Chinese People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Young group (aged 25 to 45) and elderly group (aged 65 to 85); 2. Patients undergoing elective geriatric orthopedic surgery with general anesthesia; 3. ASA physical status classification I to III; 4. Informed consent, voluntary participation in the trial, and signing of the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals with severe cardiac, pulmonary, hepatic, or renal dysfunction and coagulation abnormalities; 2. Those with a history of mental illness or long-term use of psychiatric medications (dementia, schizophrenia), chronic analgesic medication history, or history of alcohol abuse; 3. Participants who have been involved in another clinical drug study within the past 6 months; 4. Individuals allergic to the trial medication; 5. Pregnant or breastfeeding women; 6. Surgical blood loss exceeding 800 ml.

Design outcomes

Primary

MeasureTime frame
The plasma concentration of ciprofol at each time point;

Secondary

MeasureTime frame
Various pharmacokinetic parameters;Hemodynamic effects of ciprofol;Dose-response relationship of ciprofol;Perioperative adverse events;Age, gender, height, weight, ideal weight and body mass index;Biochemical indexes such as liver and kidney function before and after operation;

Countries

China

Contacts

Public ContactXu Bo

Department of Anesthesiology, General Hospital of the Southern Theater of Chinese People's Liberation Army

xubo333@hotmail.com+86 138 0273 8125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026